Genetics and genomics of neurodenerative diseases.
Identification of new genetic biomarkers and therapeutic targets for Amiotrophic Lateral Sclerosis (ALS), Parkinson and Alzheimer’s diseases, using next generation sequencing and RNAseq. Characterization of pharmacogenetics biomarkers in the response and safety of treatments for neurodegenerative diseases.
Disease / disorder characterization: Genomic characterization of patients samples by microarray and RNAseq technologies
Treatment discovery: Pharmacogenetics for response and safety of treatments
Methods for diagnostic: Genetic and genomic analysis
Clinical data: DNA samples and clinical data for ALS, Parkinson and Alzheimer disease
Development of new tools / technologies / computational methods: Bioinformatics for variant analysis and RNA expresión
Keywords: genetics, pharmacogenetics, ALS, Alzheimer, RNA-seq, next generation sequencing.